Archives of General Internal Medicine

Reach Us +1 (202) 780-3397

Opinion Article - Archives of General Internal Medicine (2024) Volume 8, Issue 4

Hyperparathyroidism: Causes, Symptoms, and Management Strategies

Amanda Dana *

Department of Surgery, NorthShore University, USA

*Corresponding Author:
Amanda Dana
Department of Surgery, NorthShore University, USA
E-mail: amada54@ns.org

Received: 29-Jul-2024, Manuscript No. AAAGIM-24-145859; Editor assigned: 01-Aug-2024, PreQC No. AAAGIM-24-145859 (PQ); Reviewed:14-Aug-2024, QC No. AAAGIM-24-145859; Revised:19-Aug-2024, Manuscript No. AAAGIM-24-145859(R); Published:26-Aug-2024, DOI:10.35841/aara-8.4.243

Citation: Dana A. Hyperparathyroidism: Causes, symptoms, and management strategies. Arch Gen Intern Med. 2024;8(4):243.

Visit for more related articles at Archives of General Internal Medicine

Abstract

  

Introduction

Hyperparathyroidism is a condition characterized by the overproduction of Parathyroid Hormone (PTH) from the parathyroid glands, which are located behind the thyroid gland in the neck. This hormone plays a critical role in regulating calcium and phosphate levels in the body, and an excess can disrupt this balance, leading to a variety of health issues. Understanding the causes, symptoms, and management strategies for hyperparathyroidism is crucial for effective treatment and maintaining overall health [1, 2].

The primary cause of hyperparathyroidism is typically a benign tumor known as a parathyroid adenoma, which leads to excessive secretion of PTH. This condition is referred to as primary hyperparathyroidism. In some cases, hyperparathyroidism can also result from parathyroid hyperplasia, where multiple parathyroid glands are enlarged and overactive. A more rare cause is parathyroid carcinoma, a malignant tumor of the parathyroid glands. Secondary hyperparathyroidism, on the other hand, arises as a compensatory response to low blood calcium levels due to another underlying condition, such as chronic kidney disease. In this scenario, the parathyroid glands produce more PTH to try to normalize calcium levels. Tertiary hyperparathyroidism can occur as a progression of secondary hyperparathyroidism, where the parathyroid glands become autonomously overactive even after the underlying cause is addressed [3, 4].

Secondary hyperparathyroidism, while not caused by the parathyroid glands themselves, can lead to symptoms related to its underlying condition. For instance, chronic kidney disease can cause symptoms such as fatigue, itching, and bone pain. The body’s attempt to compensate for low calcium levels can lead to similar symptoms as those seen in primary hyperparathyroidism, such as bone pain and weakness. Tertiary hyperparathyroidism, which often follows a prolonged period of secondary hyperparathyroidism, can result in persistent high calcium levels and its associated symptoms, even after the underlying condition has been treated. Diagnosing hyperparathyroidism involves a combination of laboratory tests and imaging studies. Blood tests are essential for measuring serum calcium and PTH levels. In primary hyperparathyroidism, elevated serum calcium levels are typically found alongside elevated or normal PTH levels. Secondary hyperparathyroidism is characterized by low or normal serum calcium levels with elevated PTH levels [5, 6].

Tertiary hyperparathyroidism often presents with elevated calcium levels despite the treatment of secondary causes. Imaging studies, such as ultrasound, sestamibi scans, or CT scans, may be used to localize the overactive parathyroid tissue, especially in cases where surgery is considered. Management strategies for hyperparathyroidism depend on the type and severity of the condition, as well as the presence of symptoms and any associated complications. In primary hyperparathyroidism, the primary treatment is usually surgical. The goal of surgery is to remove the hyperactive parathyroid tissue while preserving the normal function of the remaining parathyroid glands. Parathyroidectomy, the surgical procedure to remove one or more parathyroid glands, is often recommended for patients with significant symptoms, complications such as bone loss or kidney stones, or evidence of parathyroid carcinoma. Preoperative localization studies help guide the surgical approach and improve the chances of a successful outcome [7, 8].

For patients who are not candidates for surgery or who have asymptomatic primary hyperparathyroidism, management may involve monitoring and treating symptoms. This approach includes regular monitoring of calcium and PTH levels, as well as addressing any complications that arise, such as kidney stones or bone loss. Medications such as bisphosphonates may be used to help manage bone density, while calcimimetics, which mimic the action of calcium on the parathyroid glands, can help lower PTH levels and reduce calcium levels [9, 10].

Conclusion

In conclusion, hyperparathyroidism encompasses a range of conditions resulting from overproduction of parathyroid hormone, with primary, secondary, and tertiary forms each presenting unique challenges. The causes of hyperparathyroidism vary from benign tumors and gland hyperplasia to compensatory responses to underlying conditions. Symptoms can impact various aspects of health, including bone density, kidney function, and cognitive function. Effective management typically involves a combination of surgical intervention, medical treatment, and ongoing monitoring to address symptoms and prevent complications. A thorough understanding of the condition and a tailored approach to treatment are essential for improving patient outcomes and maintaining overall health.

References

  1. Bilezikian JP, Khan AA, Silverberg SJ, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. J Bone Miner Res. 2020;37(11):2293-314.

    2. Indexed at, Google Scholar, Cross Ref

  2. Minisola S, Arnold A, Belaya Z, et al. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res. 2020;37(11):2315-29.

    3. Indexed at, Google Scholar, Cross Ref

  3. Zhang LX, Zhang B, Liu XY, et al. Advances in the treatment of secondary and tertiary hyperparathyroidism. Front Endocrinol. 2022;13:1059828.

    4. Indexed at, Google Scholar, Cross Ref

  4. Zhu CY, Sturgeon C, Yeh MW. Diagnosis and management of primary hyperparathyroidism. 2020;323(12):1186-7.

    5. Indexed at, Google Scholar, Cross Ref

  5. Newey PJ. Hereditary primary hyperparathyroidism. Endocrinol Metab Clin North Am. 2021; 50(4):663-81.

    6. Indexed at, Google Scholar, Cross Ref

  6. Hiramitsu T, Hasegawa Y, Futamura K, et al. Treatment for secondary hyperparathyroidism focusing on parathyroidectomy. Front Endocrinol. 2023;14:1169793.

    7. Indexed at, Google Scholar, Cross Ref

  7. Strebeck RJ, Schneider AM, Whitcombe DD, et al. Hyperparathyroidism in pregnancy: a review of the literature. Obstet Gynecol Surv. 2022;77(1):35-44.

    8. Indexed at, Google Scholar, Cross Ref

  8. Kim SJ, Shoback DM. Sporadic primary hyperparathyroidism. Endocrinol Metab Clin North Am. 2021;50(4):609-28.

    9. Indexed at, Google Scholar

  9. Almquist M, Isaksson E, Clyne N. The treatment of renal hyperparathyroidism. Endocr Relat Cancer. 2020;27(1):R21-34.

    10. Indexed at, Google Scholar, Cross Ref

  10. Slattery L, Hunt JP. Contemporary management of primary hyperparathyroidism. Surg Clin North Am. 2022;102(2):251-65.

    11. Indexed at, Google Scholar, Cross Ref

Get the App